SCHEMBL29797040

SCHEMBL29797040

CC(C)(C)OC(=O)N[C@H]1CSc2cc(F)c(C(=O)O)cc2NC1=O.COC(=O)c1cc2c(cc1F)SC[C@H](NC(=O)OC(C)(C)C)C(=O)N2

nearest known ligand 0.37

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 1/20 0.37
▸ HTT P42858 1/20 0.33
▸ LMNA P02545 2/20 0.33
▸ EPHX2 P34913 1/20 0.32
▸ ALOX15 P16050 1/20 0.32
▸ NFKB1 P19838 1/20 0.32
▸ NFKB2 Q00653 1/20 0.32
▸ RELA Q04206 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.31
▸ IDO1 P14902 1/20 0.31
▸ POLB P06746 1/20 0.30
▸ SMN1; SMN2 Q16637 1/20 0.30
▸ CRBN Q96SW2 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29796978 0.96 GAA (0.40) GAAHTTLMNAEPHX2ALOX15
SCHEMBL20280033 0.96 GAA (0.40) GAAHTTLMNAEPHX2ALOX15
SCHEMBL20263999 0.95 GAA (0.40) GAAEPHX2NFKB1NFKB2RELA
SCHEMBL27121024 0.95 GAA (0.40) GAAEPHX2NFKB1NFKB2RELA
SCHEMBL26962099 0.86 GAA (0.44) GAAHTTLMNAEPHX2NFKB1
SCHEMBL30675678 0.85 GAA (0.40) GAAHTTLMNAEPHX2ALOX15
SCHEMBL29270699 0.85 GAA (0.40) GAAHTTLMNAEPHX2ALOX15
SCHEMBL26961679 0.85 GAA (0.38) GAAEPHX2NFKB1NFKB2RELA
SCHEMBL31374892 0.85 GAA (0.38) GAAEPHX2NFKB1NFKB2RELA
SCHEMBL29797018 0.85 GAA (0.38) GAAEPHX2NFKB1NFKB2RELA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4291558-A1 BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER F. Hoffmann-La Roche AG (CH) 2023-12-20 — — EP disclosed
WO-2022171745-A1 BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2022-08-18 — — WO disclosed
Send feedback